Researchers tested whether measuring caffeine levels in saliva could serve as a noninvasive liver function test. They gave participants caffeine and measured how much remained in their saliva later. People with liver disease had much lower caffeine clearance compared to healthy individuals. The test correlated strongly with other liver function tests, especially the aminopyrine breath test. The study suggests this saliva-based test could be used routinely in clinical settings. The morning saliva caffeine levels alone may be enough to estimate liver function, making the test even simpler.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Current liver function tests often require invasive procedures or complex equipment. Noninvasive alternatives are limited, especially for routine use in outpatient settings. Prior research has shown that hepatic microsomal function can be assessed through drug metabolism rates. However, no widely adopted saliva-based method exists for this purpose. The need for a simple, repeatable test remains unmet. This gap motivated researchers to explore caffeine clearance as a potential indicator. Caffeine is metabolized by the liver and excreted in saliva, making it a candidate for noninvasive testing. The study aimed to determine if salivary caffeine clearance could reliably reflect liver function in patients with liver disease.
Purpose Of The Study:
The study aimed to evaluate salivary caffeine clearance (SCl) as a noninvasive liver function test. Researchers wanted to compare SCl in patients with liver disease to healthy controls. They also sought to correlate SCl with established quantitative liver function tests. The specific problem addressed was the lack of a routine, noninvasive method to assess hepatic microsomal function. The motivation came from the limitations of current diagnostic tools. A saliva-based test could improve accessibility and patient compliance. The study focused on caffeine metabolism as a potential indicator of liver health. This approach could simplify liver function monitoring in clinical practice.
SCl measures caffeine levels in saliva to assess liver microsomal function. It correlates strongly with established liver function tests like the aminopyrine breath test.
Participants received 280 mg of caffeine in decaffeinated coffee powder between noon and 4 p.m., followed by saliva samples collected before bedtime and upon waking.
Morning saliva caffeine levels showed a strong inverse correlation (Rs = -0.94) with SCl, suggesting a single-point measurement could simplify testing.
SCl was compared with indocyanine green fractional clearance, galactose elimination capacity, and the aminopyrine breath test.
Main Methods:
The study involved measuring caffeine clearance from saliva in patients with liver disease and healthy controls. Participants received 280 mg of caffeine in decaffeinated coffee powder between noon and 4 p.m. Saliva samples were collected before bedtime and upon waking. Caffeine concentrations were analyzed using an enzyme immunoassay. The study included 29 cirrhotic patients, 18 healthy controls, and 18 with noncirrhotic liver disease. Researchers calculated salivary caffeine clearance (SCl) for each group. They compared SCl values across groups and correlated them with existing liver function tests. The study also examined the relationship between morning saliva caffeine levels and SCl.
Main Results:
Salivary caffeine clearance (SCl) was significantly lower in cirrhotic patients compared to controls. The mean SCl for cirrhotics was 0.58 ± 0.45 ml per min × kg. Healthy controls had an SCl of 1.53 ± 0.46 ml per min × kg. Patients with noncirrhotic liver disease had intermediate SCl values of 0.95 ± 0.47. The difference between cirrhotic patients and controls was statistically significant (p < 0.001). SCl correlated strongly with the aminopyrine breath test (Rs = 0.80). Other correlations included indocyanine green fractional clearance and galactose elimination capacity. Morning saliva caffeine levels showed a strong inverse correlation with SCl (Rs = -0.94). These findings suggest SCl is a reliable indicator of hepatic microsomal function.
Conclusions:
The authors suggest that salivary caffeine clearance (SCl) is a noninvasive and harmless method for assessing hepatic microsomal function. The study found that SCl values in cirrhotic patients were approximately one-third of those in healthy controls. The strong correlation with established liver function tests supports its validity. The close relationship with the aminopyrine breath test (Rs = 0.80) is notable. The study also indicates that a single-point measurement of morning saliva caffeine could simplify the test. Researchers propose that SCl is suitable for routine clinical use. The findings suggest that SCl could replace more complex or invasive tests in some cases. The study does not claim that SCl is essential for all liver function assessments.
The strongest correlation was with the aminopyrine breath test (Rs = 0.80), indicating SCl's potential as a reliable liver function indicator.
The authors suggest SCl is a noninvasive, suitable test for routine use in assessing hepatic microsomal function.